Please use this identifier to cite or link to this item: https://essuir.sumdu.edu.ua/handle/123456789/87802
Or use following links to share this resource in social networks: Recommend this item
Title Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study
Authors Felip, E.
Altorki, N.K.
Zhou, C.
Vallieres, E.
Vynnychenko, Ihor Oleksandrovych  
Akopov, A.
Martinez-Marti, A.
Chella, A.
Bondarenko, I.
Ursol, G.
Levchenko, E.
Kislov, N.
Liersch, R.
Belleli, R.
McNally, V.A.
Bennett, E.
Gitlitz, B.J.
Wakelee, H.
Keywords IMpower010
present further analyses
Type Conference Papers
Date of Issue 2022
URI https://essuir.sumdu.edu.ua/handle/123456789/87802
Publisher Elsevier
License Creative Commons Attribution 4.0 International License
Citation Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study / E. Felip, N. K. Altorki, C. Zhou et al. // Annals of Oncology. 2022. Volume 33, Issue S2. S 71.
Abstract IMpower010 showed significant DFS benefit with atezo after adjuvant chemo in resected NSCLC (Felip Lancet 2021). At the interim DFS analysis, the significance boundary was crossed for the stage II-IIIA PD-L1 TC 1% population (stratified HR, 0.66; 95% CI: 0.50, 0.88), with greatest benefit in the PD-L1 TC 50% subgroup (unstratified HR, 0.43; 95% CI: 0.27, 0.68). Here we present further analyses in PD-L1 TC 50% stage II-IIIA NSCLC pts.
Appears in Collections: Наукові видання (МІ)

Views

Germany Germany
1
Greece Greece
1
Ukraine Ukraine
10
United Kingdom United Kingdom
1
United States United States
860
Unknown Country Unknown Country
431
Vietnam Vietnam
209

Downloads

Denmark Denmark
1
France France
1
Japan Japan
859
Netherlands Netherlands
1
United Kingdom United Kingdom
1
United States United States
859
Unknown Country Unknown Country
432
Vietnam Vietnam
1

Files

File Size Format Downloads
Felip_et_al_Atezolizumab_2022.pdf 156,83 kB Adobe PDF 2155

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.